Medical marijuana company GW Pharmaceuticals (NASDAQ: GWPH) beat market expectations on revenue and earnings for the first quarter of 2019, sending shares climbing over 6% in after-market hours on Monday.
Total revenue amounted to $39.2 million compared to $3 million in the year-ago period.
Net loss for the quarter was $50.1 million, or $0.14 per share, compared to $69.5 million, or $0.20 per share in the prior year.
Epidiolex had net sales of $33.5 million in the US during the first quarter. Over 7,600 patients have received Epidiolex prescriptions since launch and the pharmacy distribution network now includes over 145 distribution points. The company plans to launch Epidiolex in five major European markets by the end of this year.
GW Pharma achieved positive results for Epidiolex in the Phase 3 trial in Tuberous Sclerosis Complex and expects the sNDA submission to take place in the fourth quarter of 2019. The company expects to start a pivotal Phase 3 trial in Rett Syndrome in the second quarter of 2019. The company also commenced an open label study in Rett syndrome and seizures for CBDV.
GW Pharma closed a transaction to sell the Rare Pediatric Disease Priority Review Voucher for $105 million on April 5, 2019. The sale will be reflected in the company’s second quarter 2019 results.
The UK-based firm enjoys both the status of a ‘red hot’ cannabis stock, as well as the general acceptance for a pharma company. In the trailing 52 weeks, the stock has gained 28%.
Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
